Group 1 - The company, Easybio, announced its participation in the "2025 Annual Online Collective Reception Day for Investors of Listed Companies in Shenzhen" [2] - The event is organized by the Shenzhen Securities Regulatory Bureau and the China Securities Investor Services Center, in collaboration with the Shenzhen Listed Companies Association and Shenzhen Panorama Network Co., Ltd. [2] - The scheduled time for the event is November 20, 2025, from 15:40 to 17:00 [2]

一、募集资金基本情况 | 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-075 | | --- | --- | --- | | 债券代码：123220 | 债券简称：易瑞转债 | | 深圳市易瑞生物技术股份有限公司 关于募集资金专项账户全部注销完成的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 深圳市易瑞生物技术股份有限公司（以下简称"公司"）近日完成了全部募 集资金专项账户的注销，现将相关情况公告如下： 1、首次公开发行股票募集资金管理情况 2021年2月5日，公司分别在中国银行深圳罗岗支行、上海浦东发展银行深圳 分行科技园支行、平安银行深圳南头支行开立了首次公开发行股票募集资金专项 账户，并会同保荐机构东兴证券股份有限公司（以下简称"东兴证券"）分别与 上述商业银行签订了《募集资金三方监管协议》，明确了各方的权利和义务。 1 号"《验资报告》。 二、募集资金存放与管理情况 （一）募集资金管理情况 公司依照《上市公司募集资金监管规则》等有关法律法规、规范性文件的规 定和要求，结合公司实际情况，制定了《募集资金管理制度》，公司 ...

本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 11 月 20 日（周四）15:40-17:00。 届时公司董事长、总经理肖昭理先生，董事、副总经理、董事会秘书李文天 女士，财务总监王广生先生将通过网络文字形式与投资者进行沟通交流，欢迎广 大投资者踊跃参与！ 特此公告。 深圳市易瑞生物技术股份有限公司 董事会 深圳市易瑞生物技术股份有限公司 关于参加 2025 年度深圳辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流工作，深圳市易瑞生物技术股份有限公司 （以下简称"公司"）将参加由深圳证监局和中证中小投资者服务中心指导、深 圳上市公司协会与深圳市全景网络有限公司联合举办的"2025 年度深圳辖区上 市公司投资者网上集体接待日活动"，现将相关事项公告如下： | 证券代码：300942 | 证券简称：易瑞生物 | 公告编号：2025-07 ...

Summary of Key Points Core Viewpoint - The A-share market experienced significant block trading activity on November 12, with a total transaction volume of 1.91 billion yuan across 66 stocks, indicating notable investor interest in specific companies [1]. Group 1: Trading Activity - The top three companies by transaction volume were Huali Group (974 million yuan), Century Huato (111 million yuan), and Chunfeng Power (77.24 million yuan) [1]. - A total of 10 stocks were traded at par value, 9 stocks at a premium, and 47 stocks at a discount [1]. Group 2: Premium and Discount Rates - The stocks with the highest premium rates were Tom Cat (18.6%), Beijing Bank (9.77%), and AVIC Chengfei (9.04%) [1]. - The stocks with the highest discount rates were Tengya Precision (23.88%), Lexin Technology (20.22%), and Wens Foodstuff (19.27%) [1]. Group 3: Institutional Buying and Selling - The ranking of institutional buying was led by Huali Group (974 million yuan), followed by Century Huato (111 million yuan) and Chunfeng Power (77.24 million yuan) [2]. - The top stocks sold by institutional investors included Century Huato (111 million yuan), followed by Hengrui Medicine (36.02 million yuan) and Haowei Group (26.44 million yuan) [2].

Group 1 - The core point of the article highlights the trading activity of Yirui Biological, which saw a closing price increase of 1.68% to 10.90 yuan on November 12 [1] - Two block trades were executed, each at a price of 9.76 yuan for 250,000 shares, totaling a transaction amount of 2.44 million yuan, with a discount rate of -10.46% [1] - Over the past three months, Yirui Biological has recorded 15 block trades with a total transaction value of 55.7766 million yuan [1] Group 2 - In the last five trading days, the stock has experienced a cumulative decline of 1.89%, with a net outflow of 42.9203 million yuan from major funds [1]

Core Viewpoint - The article highlights the growth and strategic focus of Yirui Biological, a leading player in the domestic food safety rapid testing industry, emphasizing its shift towards food safety testing and animal diagnostics after divesting its less profitable IVD business [3][5]. Food Safety Rapid Testing - Yirui Biological has established a comprehensive testing system covering all aspects of the food supply chain, including feed, breeding, production, processing, distribution, and retail [3]. - The company has a significant advantage in dairy product testing, gradually replacing most imported products in the domestic market and receiving certifications from various international authorities [3]. - Continuous high R&D investment has led to the development of two major technological barriers: self-synthesis of antigens and antibodies, and efficient pre-treatment technology, with self-synthesis being the core barrier [3]. Animal Diagnostics - Initially focused on economic animal diagnostics, Yirui Biological is expanding into the pet diagnostics market, which is expected to contribute to future growth [4]. - The company plans to develop services related to pet geriatric disease prevention and vaccines, as well as extend into the pet consumer sector to create a diversified business ecosystem [4]. Strategic Partnerships - In April 2025, Yirui Biological signed a significant cooperation agreement with global biotech giant Chr. Hansen, valued at approximately 600 million yuan, focusing on dairy product testing [4]. - This partnership is seen as a milestone for the company's international expansion, with expectations for continued large orders and potential diversification into non-dairy products [4]. Investment Outlook - Yirui Biological is positioned as a leader in the domestic food safety rapid testing sector, with a strategic focus shift expected to enhance performance [5]. - The company forecasts net profits of 25 million yuan, 50 million yuan, and 70 million yuan for 2025-2027, representing year-on-year growth rates of 44.9%, 100.3%, and 40.2% respectively [5]. - A DCF model estimates the company's overall valuation at 6 billion yuan, with a target price of approximately 15 yuan, initiating coverage with a "recommended" rating [5].

Core Insights - Shenzhen Yirui Biotechnology Co., Ltd. reported a significant improvement in its financial performance for the third quarter of 2025, with a notable increase in revenue and a return to profitability in net profit after deducting non-recurring items [1] Financial Performance - For the first three quarters of 2025, the company achieved operating revenue of 186 million yuan, representing a year-on-year growth of 17.45% [1] - The net profit attributable to the parent company reached 18.02 million yuan, with a remarkable third-quarter revenue of 76.35 million yuan, up 40.34% year-on-year [1] - The company turned around its net profit after deducting non-recurring items, reaching 3.73 million yuan for the first three quarters, and 5.79 million yuan for the third quarter alone [1] Research and Development - The company maintained strong investment in research and development, with R&D expenses amounting to 30.82 million yuan in the first three quarters of 2025, an increase of 7.00% year-on-year [1] - R&D investment accounted for 16.60% of the company's revenue, indicating a commitment to innovation and technology advancement [1] Strategic Initiatives - The company is actively advancing the construction of an automated intelligent food safety testing platform and is strategically positioning itself in the chemiluminescence technology sector [1] - By leveraging a dual approach of "automated intelligence + technology platform," the company aims to reinforce its technological advantages and drive long-term growth [1]

Financial Performance - The company's operating revenue for the current period is 76,346,216.83 CNY, representing a 40.34% increase compared to the same period last year [2] - The net profit attributable to shareholders is 15,683,546.58 CNY, showing a significant increase of 187.43% year-on-year [2] - The net profit after deducting non-recurring gains and losses is 5,785,957.24 CNY, which is a 225.48% increase compared to the same period last year [2] - The basic earnings per share (EPS) is 0.0391 CNY, reflecting a 187.50% increase year-on-year [2] Financial Indicators - Total assets at the end of the reporting period amount to 1,481,560,034.85 CNY, a 1.67% increase from the end of the previous year [2] - The equity attributable to shareholders is 908,090,377.01 CNY, which is a 4.50% increase compared to the previous year [2] - The weighted average return on equity is 1.78%, up from 1.14% in the same period last year [2] Cash Flow Analysis - The net cash flow from operating activities for the year-to-date is 7,828,976.36 CNY, which has decreased by 51.16% compared to the previous year [2] - The cash received from the disposal of fixed assets is 29,329,300.38 CNY, indicating a significant increase of 10,541.12% compared to the previous period [7] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 16,436 [9] - The largest shareholder, 易瑞(海南)创业投资有限公司, holds 32.68% of the shares, amounting to 132,369,971 shares [9] - The second-largest shareholder, 朱海, holds 14.85% of the shares, totaling 60,171,195 shares [9] Changes in Financial Position - Cash and cash equivalents increased by 53.31% to 449,803,934.39 CNY, primarily due to the redemption of financial products [7] - The company's inventory increased by 43.24% to 57,910,460.72 CNY, attributed to an increase in stock preparation [7] - The company's fixed assets rose by 57.10% to 570,435,095.39 CNY, mainly due to the completion of the 易瑞产业园 project [7]

Core Points - The company ensures that the content of the quarterly report is true, accurate, and complete, with no false records or misleading statements [2][8] - The third-quarter financial report has not been audited [3][7] Financial Data - The company does not require retrospective adjustments or restatements of previous annual accounting data [3] - There are no non-recurring profit and loss items applicable for the reporting period [3][4] - The company confirms that there are no changes in major accounting data and financial indicators that require explanation [5] Shareholder Information - The total number of ordinary shareholders and the number of preferred shareholders have changed due to stock issuance and other reasons [5] - There are no changes in the top ten shareholders or the top ten unrestricted circulating shareholders due to stock lending activities [5][6] Board Meeting - The company's board meeting was held on October 27, 2025, with all seven directors present, complying with legal and regulatory requirements [9][10] - The board approved the third-quarter report and the appointment of a new member to the strategic committee [10][11]

Core Viewpoint - 易瑞生物 reported a significant increase in both revenue and net profit for the first three quarters of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company's operating revenue for the first three quarters reached 186 million yuan, representing a year-on-year growth of 17.45% [1] - The net profit attributable to shareholders was 18.02 million yuan, showing a remarkable year-on-year increase of 362.49% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 3.73 million yuan, reflecting a year-on-year growth of 137.78% [1] - Basic earnings per share were reported at 0.0449 yuan [1]